AR041069A1 - Composicion de tolterodina liquida oral - Google Patents
Composicion de tolterodina liquida oralInfo
- Publication number
- AR041069A1 AR041069A1 ARP030103101A ARP030103101A AR041069A1 AR 041069 A1 AR041069 A1 AR 041069A1 AR P030103101 A ARP030103101 A AR P030103101A AR P030103101 A ARP030103101 A AR P030103101A AR 041069 A1 AR041069 A1 AR 041069A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- concentration
- tolterodine
- therapeutically effective
- agent
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 10
- 239000007788 liquid Substances 0.000 title abstract 3
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 title abstract 3
- 229960004045 tolterodine Drugs 0.000 title abstract 3
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 title abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 235000003599 food sweetener Nutrition 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003765 sweetening agent Substances 0.000 abstract 2
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000020629 overactive bladder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composición farmacéutica en forma de un líquido administrable por vía oral comprende agua que tiene disuelta una sal soluble en agua farmacéuticamente aceptable de un compuesto relacionado con la tolterodina a una concentración terapéuticamente eficaz de la composición. La composición tiene un pH de aproximadamente 2 a aproximadamente 6 y comprende adicionalmente un agente edulcorante y un agente antimacrobiano a una concentración que es antimicrobianamente eficaz al pH de la composición. La composición es útil para tratar un trastorno mediado por receptores muscarínicos, más particularmente vejiga hiperactiva, en un paciente, mediante administración por vía oral al mismo de una cantidad terapéuticamente eficaz de la composición. Reivindicación 1: Una composición farmacéutica en forma de un líquido administrable por vía oral, caracterizada porque comprende la composición agua que tiene disuelta una sal soluble en agua farmacéuticamente aceptable de un compuesto relacionado con la tolterodina a una concentración terapéuticamente eficaz en la composición; donde la composición tiene un pH de aproximadamente 2 aproximadamente 6, preferiblemente de aproximadamente 3 aproximadamente 5 y más preferiblemente de aproximadamente 3,5 a aproximadamente 4,5, y comprende adicionalmente un agente edulcorante y un agente antimicrobiano a una concentración que es antimicrobianamente eficaz al pH de la composición.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40642902P | 2002-08-28 | 2002-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041069A1 true AR041069A1 (es) | 2005-04-27 |
Family
ID=31978300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103101A AR041069A1 (es) | 2002-08-28 | 2003-08-27 | Composicion de tolterodina liquida oral |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7101888B2 (es) |
| EP (1) | EP1536780A1 (es) |
| JP (1) | JP2006500381A (es) |
| AR (1) | AR041069A1 (es) |
| AU (1) | AU2003265680A1 (es) |
| BR (1) | BR0313714A (es) |
| CA (1) | CA2496806A1 (es) |
| MX (1) | MXPA05002302A (es) |
| TW (1) | TW200413027A (es) |
| WO (1) | WO2004019925A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080066997A (ko) | 2005-11-10 | 2008-07-17 | 바스프 에스이 | 유해 진균 방제용 트리티코나졸을 위한 완화제로서의피라클로스트로빈의 용도 |
| CZ298448B6 (cs) * | 2006-08-09 | 2007-10-03 | Zentiva, A. S. | Farmaceutická kompozice s obsahem tolterodinu |
| US8871275B2 (en) | 2007-08-08 | 2014-10-28 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
| US20090214665A1 (en) * | 2008-02-26 | 2009-08-27 | Lai Felix S | Controlled Release Muscarinic Receptor Antagonist Formulation |
| CN102238954A (zh) | 2008-11-04 | 2011-11-09 | 肯塔基大学研究基金会 | 基于d-塔格糖的组合物以及用于预防和治疗动脉粥样硬化、代谢综合征及其症状的方法 |
| EP2386289A1 (en) * | 2010-04-29 | 2011-11-16 | Ipsen Pharma S.A.S. | Clay compositions |
| DE102012202193A1 (de) | 2012-02-14 | 2013-08-14 | Evonik Degussa Gmbh | pH-eingestelltes Süßungsmittel |
| US8568747B1 (en) | 2012-10-05 | 2013-10-29 | Silvergate Pharmaceuticals, Inc. | Enalapril compositions |
| US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
| US9669008B1 (en) | 2016-03-18 | 2017-06-06 | Silvergate Pharmaceuticals, Inc. | Enalapril formulations |
| GR1009534B (el) * | 2017-11-21 | 2019-05-31 | Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. | Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν υδροχλωρικη οξυβουτυνινη |
| CN111925294A (zh) * | 2020-07-06 | 2020-11-13 | 济南大学 | 一种托特罗定帕莫酸盐及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000057548A (ko) * | 1996-12-13 | 2000-09-25 | 알프레드 엘. 미첼슨 | 광학적 전송물질 및 결합재 |
| SE9803871D0 (sv) * | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| US20030060513A1 (en) * | 2001-09-27 | 2003-03-27 | Arneric Stephen P. | Pharmaceutical composition |
| US7005449B2 (en) * | 2002-04-23 | 2006-02-28 | Pharmacia & Upjohn Company | Tolterodine salts |
-
2003
- 2003-08-25 AU AU2003265680A patent/AU2003265680A1/en not_active Abandoned
- 2003-08-25 JP JP2004531469A patent/JP2006500381A/ja not_active Withdrawn
- 2003-08-25 EP EP03791779A patent/EP1536780A1/en not_active Withdrawn
- 2003-08-25 WO PCT/US2003/026675 patent/WO2004019925A1/en not_active Ceased
- 2003-08-25 MX MXPA05002302A patent/MXPA05002302A/es not_active Application Discontinuation
- 2003-08-25 US US10/647,816 patent/US7101888B2/en not_active Expired - Fee Related
- 2003-08-25 CA CA002496806A patent/CA2496806A1/en not_active Abandoned
- 2003-08-25 BR BR0313714-7A patent/BR0313714A/pt not_active IP Right Cessation
- 2003-08-27 AR ARP030103101A patent/AR041069A1/es not_active Application Discontinuation
- 2003-08-28 TW TW092123749A patent/TW200413027A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20050032905A1 (en) | 2005-02-10 |
| JP2006500381A (ja) | 2006-01-05 |
| WO2004019925A1 (en) | 2004-03-11 |
| EP1536780A1 (en) | 2005-06-08 |
| BR0313714A (pt) | 2005-06-28 |
| AU2003265680A1 (en) | 2004-03-19 |
| US7101888B2 (en) | 2006-09-05 |
| CA2496806A1 (en) | 2004-03-11 |
| TW200413027A (en) | 2004-08-01 |
| MXPA05002302A (es) | 2005-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4970819A1 (es) | Tratamiento de disfuncion sexual femenina en una hembra humana | |
| AR028299A1 (es) | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. | |
| BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| CO5190689A1 (es) | Sales de tramadol formadas por tramadol y un edulcorante y formas farmaceuticas que contienen dichas sales | |
| BR9408378A (pt) | Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos | |
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| CO5570677A2 (es) | Quinolinilpirrolopirazoles | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
| BR9916114A (pt) | Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina | |
| CL2008003938A1 (es) | Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00). | |
| TR200103613T2 (tr) | Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler. | |
| ES2155093T3 (es) | Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa). | |
| AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
| EE200200107A (et) | Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks | |
| CO5590913A2 (es) | Terapia de combinacion antivirica | |
| JP2004501939A5 (es) | ||
| BR0313714A (pt) | Composição oral de tolterodina lìquida | |
| CA2433833A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
| AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
| PE20020387A1 (es) | Uso de una combinacion de salmeterol y fluticasona | |
| WO2004105690A3 (en) | Treatment of chronic pain associated with drug or radiation therapy | |
| KR970705390A (ko) | 비마약성 진통제(non-narcotic analgesic) 및 진통효과 향상제(analgesia enhancer)를 포함하는 통증 완화 조성물(COMPOSITION ALLEVIATING PAIN, CONTAINING A NON-NARCOTIC ANALGESIC AND AN ANALGESIA ENHANCER) | |
| CO5060499A1 (es) | Metodos y composiciones para el tratamiento de enfermedad de reflujo gastroesofagico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |